Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in BFLY.

← Back to Free Index

BFLY

Analysis as of: 2026-04-14

Butterfly Network, Inc.

Butterfly sells handheld ultrasound devices plus cloud software, AI tools, and workflow products to clinicians, health systems, educators, and partners.

ai hardware healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Regulated imaging platform with real but bounded upside

The company has moved beyond a simple handheld-device story, but it still needs to prove that software, compliance, and partner channels can become repeatable value drivers. The upside is attractive if that mix shift happens, yet the case still sits inside a disciplined medtech framework.

Analysis

Thesis

Butterfly has a credible path from niche handheld-ultrasound vendor to a regulated imaging platform with higher-value software, compliance, and embedded licensing layers; if it converts HomeCare, enterprise workflow, and partner APIs into repeatable revenue, the stock can compound above normal medtech rates without needing a heroic software rerating.

Last Economy Alignment

AI lowers training and workflow friction for handheld ultrasound, and Butterfly controls real hardware, trust, and workflow surfaces. The limiter is that larger imaging vendors can still bundle against it, so value capture is positive but not dominant.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.8x (from 5 most recent analyses)

Reasoning

I underwrite solid but not explosive upside. The company already has a real product, improving margins, and several additive paths, but most of the payoff still depends on converting regulated workflow and embedded opportunities into repeatable contracts. My case assumes revenue compounds well above normal medtech, while valuation stays in a mixed medtech-plus-software range rather than re-rating to pure SaaS levels.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not technology failure but partial success. Butterfly can keep growing probes while still failing to become a true workflow and embedded platform, which would leave it as a subscale device company facing incumbent bundling, regulatory pacing, and supplier concentration. The upside is real, but it depends on turning recent proof points into repeatable commercial motions.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material company disclosure appeared in the last 7-10 days; the setup is still defined by the February earnings beat and March 30 FDA clearance.
The March 30 FDA clearance moved Butterfly's gestational-age AI from promising feature to permissioned product, which modestly improves confidence in AI monetization.
No first commercial HomeCare contract or Beam Steering API release has been disclosed yet, so the near-term re-rating gates remain open.

Thesis update

The core thesis is unchanged, but the FDA-cleared gestational-age tool adds evidence that Butterfly can commercialize AI inside real regulatory constraints, not just market it.

Forecast update

Recent proof points made the upside mix shift slightly more concrete, especially around Embedded economics and AI productization, so the payoff looks somewhat cleaner than before.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.42

They control the ultrasound chip, the device, and part of the hospital workflow around it, so AI can make the product easier to use and broaden who can scan. The risk is that bigger imaging vendors can bundle similar tools and regulation slows how fast Butterfly can turn developer and AI plans into durable revenue.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$5.56

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research